THE EFFICACY OF TREATMENT IN STAGE III AND IV AND SOME FACTORS RELATED WITH THE PANCREATIC CANCER AT K HOSPITAL

Hoàng Minh Lý1,, Đào Văn Tú2
1 Hanoi Medical University
2 K Hospital

Main Article Content

Abstract

Objectives: To evaluate the efficacy of treatment in stage III, IV and some factors related with the pancreatic cancer at K hospital. Patients and methods: 154 patients diagnosed with locally advanced or metastatic pancreatic cancer at K hospital were divided into 3 groups: chemotherapy group may be accompanied by palliative surgical procedures; the non-chemotherapy group received palliative surgical procedures; and untreated patients’ group. Result: In the group of 38 untreated patients, the median overall survival was 3.3 months (95% confidence interval 2.9 to 3.7 months). In 22 non-chemotherapy patients who underwent Palliative surgical procedures had a median overall survival of 3.9 months (95% CI 3.1-4.8 months). In 94 patients receiving chemotherapy: We found that none of patient showed a complete response, the partial response rate was 17%, 37.2% of the patients were stable and 45.7% of the patients had progressive disease. The median progression-free survival was 3.9 months (95% confidence interval, 3.3 to 4.5 months). The median overall survival was 8.2 months (95% confidence interval, 6.5 to 9.8 months). Three hundred ninety-one cycles were administered with 154 patients, grade 3-4 toxicity per patient was 10.2% for neutropenia, 6.9% for thrombocytopenia, 7.6% for hematological toxicities, 6.9% for anemia. grade 3 for 4.2% alanine aminotransferase or aspartate aminotransferase. No patient had grade 4 for alanine aminotransferase or aspartate aminotransferase.

Article Details

References

1. Nguyễn Bá Đức, Trần Văn Thuấn, Nguyễn Tuyết Mai (2010). Ung thư tụy. Điều trị nội khoa bệnh ung thư. Nhà xuất bản Y học, 189 - 199
2. Ferlay J., Soerjomataram I., Dikshit R. và cộng sự. (2015). Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer, 136(5), E359-386.
3. Genkinger J.M., Spiegelman D., Anderson K.E. và cộng sự. (2009). ALCOHOL INTAKE AND PANCREATIC CANCER RISK: A POOLED ANALYSIS OF FOURTEEN COHORT STUDIES. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol, 18(3), 765–776.
4. Eisenhauer E.A., Therasse P., Bogaerts J. và cộng sự. (2009). New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer, 45(2), 228–247.
5. Wang Yi, Xiao Xiuying, et al. (2018), "A Survival Model in Locally Advanced and Metastatic Pancreatic Ductal Adenocarcinoma", Journal of Cancer, 9(7), pp. 1301-1307.
6. Heinemann V., Quietzsch D., Gieseler F. và cộng sự. (2006). Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol Off J Am Soc Clin Oncol, 24(24), 3946–3952.
7. Cunningham D., Chau I., Stocken D.D. và cộng sự. (2009). Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol Off J Am Soc Clin Oncol, 27(33), 5513–5518.
8. Colucci G, Roberto Labianca et al (2010), “Randomized phase III trial of Gemcitabine plus Cisplatin compared with Single-Agent Gemcitabine as First-line treatment of patients with advanced pancreatic cancer: The GIP-1 study”, J Clin Oncol, 28, pp 1645-1651.